NCT03806426View on ClinicalTrials.gov

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2024

Conditions
Familial Adenomatous Polyposis
Interventions
DRUG

Eicosapentaenoic acid free fatty acid (EPA-FFA)

500mg capsule, two 500mg capsules to be taken twice daily for 24 months

DRUG

Placebo

500mg capsule, two 500mg capsules to be taken twice daily for 24 months

Trial Locations (1)

40138

University of Bologna and St.Orsola-Malpighi Hospital, Bologna

All Listed Sponsors
lead

S.L.A. Pharma AG

INDUSTRY